NextCure
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 82
- Market Cap
- -
- Website
- http://www.nextcure.com
- Introduction
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.
Clinical Trials
8
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: SIM0505 for injection
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- NextCure, Inc.
- Target Recruit Count
- 414
- Registration Number
- NCT06792552
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇨🇳The first medical center of PLA general hospital, Beijing, Beijing, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Conditions
- Ovarian CancerEndometrial CancerBreast CancerBiliary Tract CancerNon-Small Cell Lung CancerAdvanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- NextCure, Inc.
- Target Recruit Count
- 145
- Registration Number
- NCT06774963
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Washington University, Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
- Conditions
- Relapsed or Refractory Chronic Myelomonocytic LeukemiaRelapsed or Refractory Myelodysplastic SyndromeRelapsed or Refractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- NextCure, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05787496
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
- Conditions
- Ovarian CancerColo-rectal CancerAdvanced or Metastatic Solid TumorsLung CancerMicrosatellite Instability HighMicrosatellite StableEndometrial CancerCervical CancerEsophageal CancerMicrosatellite Instability Low
- Interventions
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- NextCure, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT05572684
- Locations
- 🇺🇸
Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸Rocky Mountain Cancer Centers, Aurora, Colorado, United States
🇺🇸St. Elizabeth Edgewood Hospital, Edgewood, Kentucky, United States
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
- Conditions
- Advanced or Metastatic Solid TumorsBreast CancerOvarian CancerNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- NextCure, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04875806
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸The University of Chicago Medicine and Biological Sciences, Chicago, Illinois, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
- Prev
- 1
- 2
- Next